TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01356186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post Admission Cognitive Therapy (PACT)
Description: Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
Study: NCT02418559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 (300 mg)
Description: Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 (600 mg)
Description: Participants will receive JNJ-63623872 600 mg (2\*300 mg) tablet orally once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63623872 (1200 mg)
Description: Participants will receive JNJ-63623872 1200 mg (4\*300 mg) tablet orally once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo tablet orally once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo tablet orally once on Day 1 under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
Study: NCT02321215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Introductory Disease Education
Description: This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
Study: NCT01547572

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: The control group will receive a leaflet only
Description: The control group will receive a leaflet only
Study: NCT05340764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab is an effective and commonly used medication to treat patients with IBD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab is an effective and commonly used medication to treat patients with IBD
Study: NCT00646802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: 1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
Study: NCT01748435

Intervention type: DRUG
Intervention: Qutenza
Description: Single treatment with Qutenza
Study: NCT02599168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Study: NCT03269032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Diet
Description: According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period.
Study: NCT00134823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight based dosing decision support
Description: weight based dosing decision support
Study: NCT04037787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
Study: NCT03120182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Patients will receive placebo medication 100mg daily for 12 days after randomization
Study: NCT03269032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: American Diet
Description: According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, \>11% Saturated Fatty Acids, \<12% Monounsaturated Fatty Acids, and \>8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-style Diet
Description: The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-style Diet
Description: The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, \<7% Saturated Fatty Acids, \>18% Monounsaturated Fatty Acids and \<5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period.
Study: NCT03450031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAC (no drug/no device)
Description: Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NAC (no drug/no device)
Description: Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
Study: NCT01625793

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-alpha
Description: Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-alpha
Description: Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
Study: NCT00486343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton CR
Description: Zileuton CR tablets 2x600mg BID for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 2x600mg BID for 24 weeks
Study: NCT04116931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch ticagrelor to clopidogrel
Description: Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch ticagrelor to clopidogrel
Description: Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch ticagrelor to clopidogrel
Description: Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch ticagrelor to clopidogrel
Description: Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
Study: NCT02769091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-45478
Description: 80 mg (2x40mg) tablets once daily for up to 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04080973

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 24 hour urine collection
Description: 24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
Study: NCT00826501

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyst-gastrostomy
Description: After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical cyst-gastrostomy
Description: After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
Study: NCT05237765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled (automatic) massage
Description: Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: controlled (automatic) massage
Description: Massage methods that are performed with mechanical methods are called automated massage. Automated massage is also individual-controlled massage. This is because in automated massage, to relax, solve or reduce their pain, the individual applies the massage under their own control or under the control of someone else through a controller in a way where the duration and intensity of the massage in the body part of application vary. Individual-controlled massage devices may be in the form of chairs, cushions, beds and mattresses. These massage devices have functions such as vibrating, applying vacuum, imitating manual massage motions and applying heat.
Study: NCT01936844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (high dose)
Description: Anakinra 100 mg daily twice daily for days 1, 2, and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (standard dose)
Description: Anakinra 100 mg daily for days 4-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for days 1, 2, and 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily for days 4-14
Study: NCT02158156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
Study: NCT01486446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XPF-002
Description: XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
Study: NCT02206854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-flurbiprofen
Description: 200 mg gelatine capsule once orally
Study: NCT03023215

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meditation
Description: Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram
Description: Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram
Description: Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalogram
Description: Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate
Description: Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart Rate
Description: Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Heart Rate
Description: Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
Study: NCT03426111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)
Description: This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle modification
Description: Hypocaloric diet and moderate physical exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification
Description: Hypocaloric diet and moderate physical exercise
Study: NCT04092556

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
Study: NCT02553018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study: NCT01779440

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Electronic Decision Support System

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Electronic Decision Support System
Study: NCT02869243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hrBMP4
Description: Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters.
Study: NCT00586703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NK-CD56
Description: NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
Study: NCT02774941

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer
Description: Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
Study: NCT03231163

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Music
Description: Participants lie supine on a table while no music is played.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing Classical Music
Description: Participants lie supine on a table while classical music is played.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Selected Relaxing Music
Description: Participants lie supine on a table while self-selected relaxing music is played.
Study: NCT02215655

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational interviewing
Description: Motivational interviewing counselling sessions will be administered to the subjects.
Study: NCT04010565

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aged black garlic extract
Description: Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
Study: NCT01831596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ciSNaP
Description: SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
Study: NCT04221204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly selective FGFR1-3 inhibitor
Description: All subjects in each cohort will receive a single oral dose of 3D185, followed by a 7-day washout period (i.e. single-dose PK study period). Then, subjects will receive consecutive daily doses (Once daily \[QD\], 28 days/cycle) until disease progression, death, unacceptable toxicity, or withdraw of informed consent, whichever comes first. The dose limiting toxicity (DLT) evaluation period includes the single-dose PK study period and the first treatment cycle (within 35 days after the first dose). The enrolled subjects will be sequentially assigned to the planned dose cohorts according to the protocol and receive 3D185 treatment to observe the occurrence of DLT.
Study: NCT01308073

Intervention type: DEVICE
Intervention: Hemodialysis with EMIC 2 filters
Description: Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
Study: NCT01205542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Training of scapular function with strengthening exercises using bodyweight and elastic resistance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Health check and advice to continue ordinary physical activity